Editas Medicine (EDIT) Receivables (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Receivables data on file, last reported at $15.2 million in Q4 2025.

• On a quarterly basis, Receivables fell 6.7% year-over-year to $15.2 million in Q4 2025; TTM through Dec 2025 was $15.2 million, a 6.7% decrease from a year earlier, with the FY2025 full-year figure at $15.2 million, down 6.7% from the prior year.
• Receivables for Q4 2025 stood at $15.2 million, up from $8.1 million in the prior quarter.
• Over the last five years, Receivables for EDIT reached as high as $16.3 million in Q4 2024 and fell as low as $120000.0 in Q3 2022.
• Historically, Receivables has averaged $3.3 million across 5 years, with a median of $630000.0 in 2021.
• Across the five-year window, Receivables tumbled 95.59% in 2021 and soared 6352.38% in 2025, its largest moves.
• Year by year, Receivables stood at $267000.0 in 2021, then soared by 1826.97% to $5.1 million in 2022, then jumped by 98.0% to $10.2 million in 2023, then surged by 59.67% to $16.3 million in 2024, then decreased by 6.7% to $15.2 million in 2025.
• Per Business Quant data, the three most recent Receivables figures were $15.2 million in Q4 2025, $8.1 million in Q3 2025, and $588000.0 in Q2 2025.